5-Thienyltryptamine derivatives as serotonin 5-HT(1B/1D) receptor agonists: Potential treatments for migraine

Bioorganic and Medicinal Chemistry Letters

Volumn 10, Issue 9, 2000, Pages 903-905

  Meng, Charles Q ^a,b   Rakhit, Suman ^c   Lee, David K H ^d   McCallum, Kirk L ^a   Mazzocco, Lucy ^a   Dyne, Kerry ^d   Slassi, Abdelmalik ^a  

^a NPS Allelix Corp   (Canada)

^b AtheroGenics Inc   (United States)

^c MCR Research Inc   (Canada)

^d Department of Pharmacology   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

5 THIENYLTRYPTAMINE DERIVATIVES; SEROTONIN; SEROTONIN 1B AGONIST; SEROTONIN 1D AGONIST; UNCLASSIFIED DRUG;

ARTICLE; CATALYSIS; CHEMICAL MODIFICATION; CHEMICAL REACTION; DRUG POTENCY; DRUG SELECTIVITY; DRUG STRUCTURE; DRUG SYNTHESIS; STRUCTURE ANALYSIS;

CLONING, MOLECULAR; HUMANS; INDICATORS AND REAGENTS; MIGRAINE DISORDERS; RECEPTOR, SEROTONIN, 5-HT1B; RECEPTOR, SEROTONIN, 5-HT1D; RECEPTORS, SEROTONIN; SEROTONIN ANTAGONISTS; STRUCTURE-ACTIVITY RELATIONSHIP; TRYPTAMINES;

EID: 0034194427     PISSN: 0960894X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0960-894X(00)00133-5     Document Type: Article

References (18)

1. Migraine: Pharmacology and Genetics; Sandler, M.; Ferrari, M.; Harnett, S., Eds.; Altman: London, 1996.
2. Plosker M., McTavish D. Drugs. 47:1994;622.
3. Meng C.Q. Curr. Med. Chem. 4:1997;385.
4. Humphrey P.P.A., Goaadsby P.J. Cephalalgia. 14:1994;401.
5. Buzzi M.G., Bonamini M., Moskowitz M.A. Cephalalgia. 15:1995;277.
6. Bouchelet I., Cohen Z., Casee B., Seguela P., Hamel E. Mol. Pharmacol. 50:1996;219.
7. (a) Rebeck, G. W.; Maynard, K. I.; Hyman, B. T.; Moskowitz, M. A. Proc. Natl. Acad. Sci. USA 1994, 91, 3666;
8. (b) Moskowitz, M. A.; Macfarlane, R. Brain Metab. Rev. 1993, 5, 159.
9. Yu X.J., Waeber C., Castanon N., Scearce K., Hen R., Macor J.E., Chaveau J., Moskowitz M.A. Mol. Pharmacol. 49:1996;761.
10. Johnson K.W., Schaus J.M., Durkin M.M., Audia J.E., Kaldor S.W., Flaugh M.E., Adham N., Zgombick J.M., Cohen M.L., Branchek T.A., Phebus L.A. NeuroReport. 8:1997;2237.
11. Bouchelet, I.; Cohen, Z.; Seguela, P.; Hamel, E. In Migraine: Pharmacology and Genetics; Sandler, M.; Ferrari, M.; Harnett, S., Eds.; Altman: London, 1996; pp 55-66.
12. (a) Parsons, A. A.; Stutchburg, C.; Raval, P.; Kaumann, A. J. Naunyn-Schmiedeberg’s Arch. Pharmacol. 1992, 346, 592;
13. (b) Kaumann, A. J.; Parsons, A. A.; Brown, A. M. Cardiovas. Res. 1993, 24, 932.
14. Castro J.L., Collins I., Russell M.G.N., Watt A.P., Sohal B., Rathbone D., Beer M.S., Stanton J.A. J. Med. Chem. 41:1998;2667.
15. Ennis M.E., Ghazal R.L., Smith M.W., Schlachter S.K., Lawson C.F., Im W.B., Pregenzer J.F., Svensson K.A., Lewis R.A., Hall E.D., Sutter D.M., Harris L.T., McCall R.B. J. Med. Chem. 41:1998;2180.
16. Miyaura N., Yanagi T., Suzuki A. Synth. Commun. 11:1981;513.
17. Stille J.K. Angew. Chem., Int. Ed. Engl. 25:1986;508.
18. Barf T.A., de Boer P., Wikström H. J. Med. Chem. 39:1996;4717.